Related Experiment Video
Updated: Mar 19, 2026
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
Advances and Challenges in the Multidisciplinary Treatment of Retroperitoneal Infantile Fibrosarcoma in Early Life
Gaia Brunetti1,2,3, Angelo Zarfati1,2,3, Giorgio Persano3
1University of Tor Vergata, Rome, Italy.
Insights
Retroperitoneal infantile fibrosarcoma (RIFS) management has evolved with multidisciplinary approaches. Advances in surgery, interventional radiology, and targeted therapies improve outcomes for this rare pediatric tumor.
Area of Science:
- Pediatric Oncology
- Surgical Oncology
- Radiology
Background:
- Retroperitoneal infantile fibrosarcoma (RIFS) is a rare, aggressive pediatric soft tissue tumor.
- Its retroperitoneal location presents surgical challenges due to proximity to vital structures like the inferior vena cava (IVC).
Purpose of the Study:
- To illustrate the multidisciplinary management strategies for RIFS.
- To highlight evolving therapeutic approaches in RIFS treatment.
Main Methods:
- Retrospective case series of infants diagnosed with RIFS.
- Analysis of clinical presentation, imaging, histopathology, and treatment modalities.
- Review of follow-up data from a tertiary center.
Main Results:
- Three infants with RIFS were identified (median age 2 months).
- Diagnosis was confirmed via open surgical biopsy.
- Individualized, multimodal management included neoadjuvant chemotherapy, surgery, interventional radiology, and targeted therapy.
Conclusions:
- RIFS management has advanced significantly, integrating interventional radiology and targeted therapies.
- Multidisciplinary, individualized treatment balances oncological control with reduced surgical morbidity.
- Optimizing outcomes for RIFS requires a comprehensive, team-based approach.
Background And Aims:
Retroperitoneal Infantile Fibrosarcoma (RIFS) is a rare, locally aggressive pediatric soft tissue tumor. Its retroperitoneal location poses challenges due to proximity and potential invasion of critical structures such as the inferior vena cava (IVC). This study aims to illustrate the range of multidisciplinary management strategies and evolving therapeutic approaches.
Methods:
We conducted a retrospective case series of infants diagnosed with RIFS and treated at our tertiary center. Clinical presentation, imaging findings, histopathology, treatment modalities (including chemotherapy, surgery, interventional radiology, targeted therapies), and follow-up data were analyzed.
Results:
Three infants with histologically confirmed RIFS were identified, with a median age at diagnosis of 2 months (range: 0-8 months). Diagnosis was established through open surgical biopsy. Management was individualized and multimodal, including neoadjuvant chemotherapy, surgical resection, interventional radiology procedures for symptom control, and, in the most recent case, targeted molecular therapy guided by genetic profiling.
Conclusions:
Management of RIFS has significantly evolved over the last decade. Advances in surgical techniques combined with the integration of interventional radiology and novel targeted therapies allow a nuanced balance between maximizing oncological control and minimizing surgical morbidity. Multidisciplinary individualized treatment is essential to optimize outcomes in this rare and challenging pediatric tumor.
